Paul A Volberding

Summary

Country: USA

Publications

  1. ncbi Initiating HIV therapy. Timing is critical, controversial
    Paul A Volberding
    University of California, San Francisco, School of Medicine, UCSF Gladstone Institute of Virology and Immunology Center for AIDS Research, San Francisco Veterans Affairs Medical Center, USA
    Postgrad Med 115:15-8, 21, 24-6. 2004
  2. ncbi The impact of anemia on quality of life in human immunodeficiency virus-infected patients
    Paul Volberding
    Medical Service, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, CA
    J Infect Dis 185:S110-4. 2002
  3. ncbi Anemia in HIV infection: clinical impact and evidence-based management strategies
    Paul A Volberding
    University of California, San Francisco, CA, USA
    Clin Infect Dis 38:1454-63. 2004
  4. ncbi HIV therapy in 2003: consensus and controversy
    Paul A Volberding
    University of California, San Francisco, California 94121, USA
    AIDS 17:S4-11. 2003
  5. ncbi Opportunities and options for treatment research in resource-constrained settings
    Paul A Volberding
    University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    Clin Infect Dis 37:S1-3. 2003
  6. ncbi Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease
    Andy I Choi
    Department of Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Infect Dis 45:1633-9. 2007
  7. ncbi Long-term clinical consequences of acute kidney injury in the HIV-infected
    Andy I Choi
    Department of Medicine, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Kidney Int 78:478-85. 2010
  8. ncbi Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons
    Andy I Choi
    Department of Medicine, San Francisco Veterans Affairs Medical Center, and University of California, San Francisco, USA
    Circulation 121:651-8. 2010
  9. ncbi A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
  10. ncbi Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment
    Paul Volberding
    University of California San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    AIDS 23:1987-95. 2009

Research Grants

  1. UCSF-GIVI CENTER FOR AIDS RESEARCH
    Paul Volberding; Fiscal Year: 2007

Detail Information

Publications25

  1. ncbi Initiating HIV therapy. Timing is critical, controversial
    Paul A Volberding
    University of California, San Francisco, School of Medicine, UCSF Gladstone Institute of Virology and Immunology Center for AIDS Research, San Francisco Veterans Affairs Medical Center, USA
    Postgrad Med 115:15-8, 21, 24-6. 2004
    ..In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options...
  2. ncbi The impact of anemia on quality of life in human immunodeficiency virus-infected patients
    Paul Volberding
    Medical Service, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, CA
    J Infect Dis 185:S110-4. 2002
    ..The purpose of this article is to describe the effects of anemia on QOL and to provide an overview of several studies showing that QOL improves with the alleviation of anemia...
  3. ncbi Anemia in HIV infection: clinical impact and evidence-based management strategies
    Paul A Volberding
    University of California, San Francisco, CA, USA
    Clin Infect Dis 38:1454-63. 2004
    ....
  4. ncbi HIV therapy in 2003: consensus and controversy
    Paul A Volberding
    University of California, San Francisco, California 94121, USA
    AIDS 17:S4-11. 2003
    ..The present review will address both the striking advantages of HIV therapy as well as the ongoing challenges in its application...
  5. ncbi Opportunities and options for treatment research in resource-constrained settings
    Paul A Volberding
    University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    Clin Infect Dis 37:S1-3. 2003
    ..On the other hand, ones with a more observational design or that compare cohort experiences may well be feasible and able to provide information important in those settings, as well as in regions with abundant financial resources...
  6. ncbi Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease
    Andy I Choi
    Department of Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Infect Dis 45:1633-9. 2007
    ....
  7. ncbi Long-term clinical consequences of acute kidney injury in the HIV-infected
    Andy I Choi
    Department of Medicine, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Kidney Int 78:478-85. 2010
    ..Additionally, AKI affected almost one of six patients with HIV who survived at least 90 days following discharge...
  8. ncbi Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons
    Andy I Choi
    Department of Medicine, San Francisco Veterans Affairs Medical Center, and University of California, San Francisco, USA
    Circulation 121:651-8. 2010
    ..We examined the association between longitudinal measures of kidney function and albuminuria with risk of atherosclerotic CVD and heart failure in a contemporary cohort of HIV-infected individuals...
  9. ncbi A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
    ..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
  10. ncbi Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment
    Paul Volberding
    University of California San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    AIDS 23:1987-95. 2009
    ..Antiretroviral therapy in early HIV infection may enhance outcome and viral control may be better in acute versus recent infection 24 weeks after treatment interruption...
  11. ncbi Antiretroviral therapy and management of HIV infection
    Paul A Volberding
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    Lancet 376:49-62. 2010
    ....
  12. ncbi Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects
    Caroline M Behler
    Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
    Clin Infect Dis 44:1375-83. 2007
    ....
  13. ncbi Adherence, resistance, and timing: current issues in the use of new therapies
    Paul Volberding
    Department of Medicine, University of California, San Francisco, USA
    AIDS Read 12:349-50, 356-7, 368. 2002
    ..Because adherence is linked to convenience and tolerability, new agents with favorable safety profiles, low pill burdens, and little or no selection for drug resistance will be required to ensure long-term viral suppression...
  14. ncbi Anemia and HIV in the antiretroviral era: potential significance of testosterone
    Caroline Behler
    Department of Medicine, San Francisco Veterans Affairs Medical Center, University of California San Francisco, San Francisco, California 94143, USA
    AIDS Res Hum Retroviruses 21:200-6. 2005
    ..20, 95% CI 0.05-0.84), and macrocytosis (adjusted OR 0.23, 95% CI 0.09-0.61). Low testosterone levels may have a positive association and supplemental androgens a negative association with anemia in HIV disease...
  15. ncbi Racial differences in end-stage renal disease rates in HIV infection versus diabetes
    Andy I Choi
    Department of Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Am Soc Nephrol 18:2968-74. 2007
    ..HIV and diabetes carry a similar risk of ESRD among black patients, highlighting the importance of developing strategies to prevent and treat renal disease among HIV-infected black individuals...
  16. ncbi The pavia consensus statement
    Paul A Volberding
    University of California, San Francisco, USA
    AIDS 17:S170-9. 2003
  17. ncbi Introduction: the importance of identifying and treating complications of human immunodeficiency virus disease
    Paul Volberding
    University of California, San Francisco, Veterans Affairs Medical Center, San Francisco, California, USA
    J Infect Dis 185:S103-4. 2002
  18. ncbi Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  19. ncbi Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  20. ncbi Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future
    David H Henry
    Department of Oncology, Hematology, Pennsylvania Hospital, Philadelphia, PA 19106, USA
    J Acquir Immune Defic Syndr 37:1221-7. 2004
    ..Current and future research will further clarify the role of epoetin alfa in the clinical management of the HIV-infected population...
  21. ncbi Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  22. ncbi Does hepatitis C virus infection increase the risk of HIV disease progression?
    Stephen J Rossi
    JAMA 288:241-3. 2002
  23. ncbi Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  24. ncbi The New York case: lessons being learned
    Paul A Volberding
    Ann Intern Med 142:866-8. 2005
  25. ncbi Who cares for AIDS?
    Paul A Volberding
    J Gen Intern Med 17:82-3. 2002

Research Grants1

  1. UCSF-GIVI CENTER FOR AIDS RESEARCH
    Paul Volberding; Fiscal Year: 2007
    ....